Stephanie Walker on Increasing the Participation of Black Women With Metastatic Breast Cancer in Clinical Trials
2022 ASCO Annual Meeting
Stephanie Walker, a former nurse and current activist with the Metastatic Breast Cancer Alliance, discusses findings from the BECOME project (Black Experience of Clinical Trials and Opportunities for Meaningful Engagement). They show that, even though Black patients comprise between 4% and 6% of all clinical trial participants, Black women with metastatic breast cancer are willing to consider taking part if steps were taken to increase their awareness, build trust through clear communication with health-care providers, involve people of shared racial/ethnic identity and health experience, and help patients find and access trials (Abstract 1014).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
My project for ASCO this year was to include or increase participation of black men and women with metastatic breast cancer in clinical trials. First of all, I think we need to inform. We not only need to inform the patients about clinical trials, but we also need to inform you as a healthcare provider to ask us. Because the majority of the patients that were asked on this survey, if they knew about clinical trials, they didn't know. I think it is part of the job of the healthcare provider to ask us. Don't assume that we don't know about it, or we know about it and choose not to. Don't assume that we can't afford it. Don't assume that we're not educated enough to do this. Everybody needs to be informed. Next, we need to inspire. You need to inspire us as the patient. You need to help build that bond regarding trust and the healthcare provider, which is you. We need to inspire trust, even though we know the trials and tribulations in the past, we need to go forward. You need to ensure that we know where we can get in touch with people regarding the clinical trials. We also need to ensure that we know how to utilize the resources, to look for clinical trials or where to find those. Also, you need to address the barriers. Financial is the biggest barrier that we have. You need to help us by providing a meal because a clinical trial is all day. Or parking. We have childcare that we need to attend to. Help address some of those little barriers. They may seem little to you, but they are huge barriers for us. If you take care of the barriers, ensure that we know where to contact or where to enroll in clinical trials, inspire, develop the trust, and we need to inform the patient and yourself about including and talking to us about clinical trials. With that being said, we are going to do a follow-up study to reach those that we were unable to reach, which were those people in rural communities that are not connected to internet or not connected to a university-based institution, because 80% of all the cancer patients are treated in community-based cancer centers. I encourage you to look at other methods of including us in clinical trials. Instead of having me fly from the east coast to the west coast, to do a clinical trial or fly from the east coast to the west coast, to get CT scans when I can get them five minutes down the road. I need you to address some of those logistics, some of the barriers regarding finances. I also need you to know us. Get to know your patients in that 15 minutes, I know is a short period of time that you have to spend with us in the office, but you also need to inform us. Do not assume. Inform us of clinical trials.
Related Videos
The ASCO Post Staff
Richard Finn, MD, of the Geffen School of Medicine at UCLA and the Jonsson Comprehensive Cancer Center, discusses analyses from the PALOMA-2 trial on overall survival with first-line palbociclib plus letrozole vs placebo plus letrozole in women with ER-positive/HER2-negative advanced breast cancer. The study met its primary endpoint of improving progression-free survival but not the secondary endpoint of overall survival. Although patients receiving palbociclib plus letrozole had numerically longer overall survival than those receiving placebo plus letrozole, the results were not statistically significant (Abstract LBA1003).
The ASCO Post Staff
Nancy Davidson, MD, of the Fred Hutchinson Cancer Research Center, reviews results from four abstracts about the importance of long-term follow-up in studies of adjuvant endocrine therapy for hormone receptor–positive breast cancer. Because the natural history of hormone receptor–positive breast cancer is long, an effort is underway to improve selection of patients by clinical parameters or biomarkers, refine the endocrine therapy background, and administer more effective combinations of endocrine therapy with other agents.
The ASCO Post Staff
Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, and Véronique Diéras, MD, of the Centre Eugène Marquis, discuss the many challenges posed by next-generation antibody-drug conjugates (ADCs). They include side effects such as hematotoxicity, gastrointestinal toxicities, and interstitial lung disease; tumor targeting and payload release; drug resistance; and the urgent need to understand ADCs’ mechanisms of action to better sequence and combine drugs.
The ASCO Post Staff
Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Ian D. Davis, PhD, MBBS, of Monash University and Eastern Health, discuss the latest findings from ANZUP Cancer Trials Group’s ENZAMET cooperative group trial of enzalutamide in patients with metastatic hormone-sensitive prostate cancer. The results corroborate the benefit of enzalutamide with improved overall survival, and involve some exploratory subgroup analyses (Abstract LBA5004).
The ASCO Post Staff
Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, and Jeanne Tie, MBChB, MD, of Peter MacCallum Cancer Centre, discuss results from the DYNAMIC trial, in which a circulating tumor DNA (ctDNA)-guided approach reduced the use of adjuvant chemotherapy without compromising recurrence-free survival in patients with stage II colon cancer (Abstract LBA100).